Surgeon General’s report notes lack of evidence on e-cigarettes in smoking cessation January 31, 2020Vol.46 No.5By Alexandria Carolan
SU2C initiatives aim to boost diversity in cancer trials January 31, 2020Vol.46 No.5By Alexandria Carolan
Drugs & Targets FDA grants Tazverik accelerated approval as first treatment option for epithelioid sarcoma January 24, 2020Vol.46 No.04
Drugs & Targets FDA grants priority review of belantamab mafodotin for relapsed or refractory multiple myeloma January 24, 2020Vol.46 No.04
Drugs & Targets Myriad submits sPMA for BRACAnalysis CDx as companion diagnostic for Lynparza in metastatic castration-resistant prostate cancer January 24, 2020Vol.46 No.04
Drugs & Targets Health Canada approves Keytruda + Inlyta for advanced RCC January 24, 2020Vol.46 No.04
Clinical Roundup Surufatinib phase III study reaches primary endpoint in advanced pancreatic neuroendocrine tumors in China, trial to end early January 24, 2020Vol.46 No.04
Clinical Roundup Pain control strategy reduces need for opioids in patients with head and neck cancer January 24, 2020Vol.46 No.04
Drugs & Targets 9/11 responders have increased overall cancer incidence in thyroid, prostate, and leukemia cancers, study finds January 24, 2020Vol.46 No.04
